Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/11655
Title: Vancomycin AUC/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia.
Authors: Holmes, Natasha E;Turnidge, John D;Munckhof, Wendy J;Robinson, J Owen;Korman, Tony M;O'Sullivan, Matthew V N;Anderson, Tara L;Roberts, Sally A;Warren, Sanchia J C;Gao, Wei;Howden, Benjamin P;Johnson, Paul D R
Affiliation: Austin Centre for Infection Research, Department of Infectious Diseases, Austin Health, Heidelberg, Victoria, Australia.
Issue Date: 18-Jan-2013
Citation: Antimicrobial Agents and Chemotherapy 2013; 57(4): 1654-63
Abstract: A ratio of the vancomycin area under the concentration-time curve to the MIC (AUC/MIC) of ≥ 400 has been associated with clinical success when treating Staphylococcus aureus pneumonia, and this target was recommended by recently published vancomycin therapeutic monitoring consensus guidelines for treating all serious S. aureus infections. Here, vancomycin serum trough levels and vancomycin AUC/MIC were evaluated in a "real-world" context by following a cohort of 182 patients with S. aureus bacteremia (SAB) and analyzing these parameters within the critical first 96 h of vancomycin therapy. The median vancomycin trough level at this time point was 19.5 mg/liter. There was a significant difference in vancomycin AUC/MIC when using broth microdilution (BMD) compared with Etest MIC (medians of 436.1 and 271.5, respectively; P < 0.001). Obtaining the recommended vancomycin target AUC/MIC of ≥ 400 using BMD was not associated with lower 30-day all-cause or attributable mortality from SAB (P = 0.132 and P = 0.273, respectively). However, an alternative vancomycin AUC/MIC of >373, derived using classification and regression tree analysis, was associated with reduced mortality (P = 0.043) and remained significant in a multivariable model. This study demonstrated that we obtained vancomycin trough levels in the target therapeutic range early during the course of therapy and that obtaining a higher vancomycin AUC/MIC (in this case, >373) within 96 h was associated with reduced mortality. The MIC test method has a significant impact on vancomycin AUC/MIC estimation. Clinicians should be aware that the current target AUC/MIC of ≥ 400 was derived using the reference BMD method, so adjustments to this target need to be made when calculating AUC/MIC ratio using other MIC testing methods.
Internal ID Number: 23335735
URI: http://ahro.austin.org.au/austinjspui/handle/1/11655
DOI: 10.1128/AAC.01485-12
URL: http://www.ncbi.nlm.nih.gov/pubmed/23335735
Type: Journal Article
Subjects: Aged
Aged, 80 and over
Anti-Bacterial Agents.therapeutic use
Female
Humans
Male
Microbial Sensitivity Tests
Retrospective Studies
Staphylococcal Infections.drug therapy.mortality
Staphylococcus aureus.drug effects.pathogenicity
Vancomycin.pharmacokinetics.pharmacology.therapeutic use
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.